←
Loading live data…
PRICE
Loading…
REVENUE MIX
Total Revenue100%
COST
COGS17%
R&D + SG&A29%
Op Margin54%
FINANCIAL HEALTH
REVENUE
$79.7B
Growth
48%
Gross M.
83%
P/E
41.2
EV/EBITDA
28.5
Net M.
34%
FCF M.
14%
D/E
1.6
Op M.
54%
PLUG INTO YOUR DCF
Historical growth
21.6%
Analyst 5y growth
—
Forward P/E
27.1
PEG ratio
1.50
Trailing EPS
$31.10
Forward EPS
$47.30
🚩 RED FLAG SCANNER — 10-K RISK FACTORS, YEAR OVER YEAR
TAM
SIZE
—
CAGR
—
Market-size estimates aren't available for this stock right now — see Financial Health and Risk Assessment below for a fundamentals-based read instead.
RISK ASSESSMENT
LOWA mechanical base-case DCF (default assumptions) implies 117% upside to $2782.24 — take this as a rough, unverified estimate, not a target.
MEDDebt/equity of 1.60 — moderate leverage.
MEDRevenue growing 48% YoY — the multiple depends on this pace continuing; deceleration is a real risk.
🐂 BULL
LLY shows revenue grew +47.7% YoY, 54% operating margin, 102% ROE, a healthy 14% free cash flow margin — a business converting growth into real profit.
🐻 BEAR
At a P/E of 41.2 and EV/EBITDA of 28.5, the stock is priced for continued execution — any deceleration in growth or margin compression would likely pressure the multiple.
AI-powered data, computed by TreasureX · May contain inaccuracies
⚠️
All values, scores, and figures here are computed from your own assumptions and public data, for educational purposes only. This is not investment advice — TreasureX does not recommend buying or selling any security. Results change with your inputs. Please do your own research and use your own judgement before making any investment decision.